The call presented a strong financial performance with raised revenue guidance and successful product launches, despite some challenges like strong price competition and potential tariff impacts.

Company Guidance -

Q2 2025

During the Alvotech Q1 2025 earnings call, the company provided guidance by revising its full-year financial projections upward, reflecting strong performance and strategic developments. The top-line revenue guidance was increased to a range of $600 million to $700 million, while the adjusted EBITDA guidance was raised to $200 million to $280 million. Alvotech reported a $110 million increase in product revenues for the first quarter, driven by successful launches of biosimilars to Humira and Stelara. The company also achieved a positive adjusted EBITDA of $21 million and expects to be free cash flow positive in 2025. Alvotech plans to launch three new biosimilars by Q4 2025, contributing further to revenue diversification. The guidance reflects the company's robust pipeline, strategic partnerships, and the anticipated growth in biosimilar market share, particularly in the U.S. market.

Increased Revenue Guidance

Top line revenue guidance for 2025 is raised to $600 million to $700 million, and adjusted EBITDA guidance is raised to $200 million to $280 million.

Strong Financial Performance

Fourth consecutive quarter of positive adjusted EBITDA and operating profits with triple-digit increases in both product revenues and total revenues compared to the same quarter in the previous year.

Stelara Biosimilar Success

Successful launch of Stelara biosimilar in the U.S. and other markets, with a significant market share and recent FDA approval for interchangeability.

Product Pipeline Expansion

Three biosimilar filings under review in major markets, expected to launch by Q4 2025, expanding to six marketed biosimilars by early 2026.

Positive Cash Flow

Generated $17 million of positive cash flows from operations in Q1, expecting to be free cash flow positive in 2025.

Alvotech (ALVO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ALVO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 13, 2025	2025 (Q2)	-0.05 / -	0.14	―	―	―
May 07, 2025	2025 (Q1)	-0.11 / 0.35	-0.89	139.33% (+1.24)
Mar 26, 2025	2025 (Q4)	>-0.01 / -	-0.8	―
Nov 13, 2024	2024 (Q3)	-0.06 / -0.03	-0.58	94.83% (+0.55)
Aug 15, 2024	2024 (Q2)	<0.01 / 0.14	-0.06	333.33% (+0.20)
May 21, 2024	2024 (Q1)	-0.08 / -0.89	-1.24	28.23% (+0.35)
Mar 26, 2024	2024 (Q4)	- / -	-1.289	―	―	―
Mar 20, 2024	2023 (Q4)	0.04 / -0.80	-1.289	37.94% (+0.49)
Nov 28, 2023	2023 (Q3)	-0.07 / -0.58	0.02	-3000.00% (-0.60)
Aug 30, 2023	2023 (Q2)	-0.14 / -0.06	-1.02	94.12% (+0.96)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ALVO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 07, 2025	$7.94	$9.38	+18.14%
Mar 26, 2025	$11.55	$10.36	-10.30%
Nov 13, 2024	$11.93	$12.07	+1.17%
Aug 15, 2024	$11.93	$12.97	+8.72%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Alvotech (ALVO) report earnings?

Alvotech (ALVO) is schdueled to report earning on Aug 13, 2025, After Close (Confirmed).

What is Alvotech (ALVO) earnings time?

Alvotech (ALVO) earnings time is at Aug 13, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ALVO EPS forecast?

ALVO EPS forecast for the fiscal quarter 2025 (Q2) is -0.05.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing